Axonyx Inc.
Axonyx Inc.
Corporate-news announcement processed and sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
AXONYX CO-SPONSORS FIRST INTERNATIONAL WINTER-SYMPOSIUM ON:
“ALZHEIMER’S DISEASE: MODIFICATION AND MEASUREMENT OF PROGRESSION”
DECEMBER 11TH – 14TH, 2003, ZÜRS, AUSTRIA
NEW YORK, NY, December 10, 2003 — Axonyx Inc. (NASDAQ:AXYX) is co-sponsoring
the First International Winter Symposium on “Alzheimer’s disease: Modification
and Measurement” from December 11th-14th in Zürs, Austria. Invited speakers at
this meeting are some of the leading authorities in this area including
representatives from the European Regulatory Authority.
At this symposium, Axonyx has brought together leading experts in the area of
Alzheimer’s disease (AD) progression and modification to discuss the mechanisms
by which potential drugs could inhibit or arrest AD. In addition, it is hoped
that the symposium will serve to identify and seek consensus on the most
appropriate development tools that can be utilized to directly or indirectly
measure a drug’s inhibition of AD progression.
Axonyx has two compounds that could potentially inhibit AD progression;
firstly, Phenserine, its lead compound for AD currently in a Phase III clinical
trial in Europe, has a dual mechanism of action associated with
acetylcholinesterase (AchE) and Beta Amyloid Precursor Protein (b-APP)
inhibition, and secondly, Posiphen, that has only the b-APP inhibition
activity. In preclinical studies reduced b-APP levels have led to lower levels
of Amyloid beta (Ab) and clinical researchers believe that reduced levels of
amyloid beta may be a key causative factor in AD. Phenserine has previously
been shown to improve the memory of mild-to-moderate AD and may also
potentially modify disease progression based on its ability to decrease the
production of b-APP. Phenserine’s potential ability to cause this same
reduction in patients is being examined in a Phase IIB clinical study that is
now ongoing. It is intended that Posiphen, now in pre-IND development, could be
developed as an inhibitor of AD progression.
The keynote address will be by Professor Bengt Winblad of the Department of
Geriatric Medicine at the Karolinska Institute and Chief Physician at the
Huddinge Hospital in Stockholm, Sweden. Professor Winblad is also Chairman of
the Axonyx Steering Committee that oversees the ongoing clinical trials with
Phenserine. Other notable speakers include, Steven H. Ferris, Ph.D., Friedman
Professor of the Alzheimer Disease Center at New York University (NYU) School
of Medicine, Executive Director of NYU’s Silberstein Institute for Aging and
Dementia, and Principal Investigator of their NIA-Supported Alzheimer Disease
Center, Nigel Greg, Ph.D., Chief, Drug Design & Development, from the National
Institute on Aging, National Institutes of Health, Baltimore, MD, and Kumar
Sambamurti, Ph.D., Associate Professor of Physiology and Neuroscience, from the
Medical University of South Carolina, Charleston, SC.
“As a Company with a number of drugs in development, notably Phenserine and
Posiphen, that may potentially have an effect on Alzheimer’s disease
progression, we are very excited to be co-sponsoring this educational event on
Alzheimer’s disease,” stated Gosse B. Bruinsma MD, President and COO of
Axonyx, “With the increasing numbers of people being diagnosed with
Alzheimer’s, now at over 12 million worldwide, it is important that we bring
together the experts to focus on how we can best try to stop it”.
Full details of the symposium are available on the Axonyx web site at
http://www.axonyx.com.
____________________________________
About Axonyx
Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the
acquisition and development of proprietary pharmaceutical compounds and new
technologies useful in the diagnosis and treatment of Alzheimer’s disease,
human memory disorders and prion-based illnesses such as Mad Cow disease.
This press release may contain forward-looking statements or predictions. These
statements represent our judgment to date, and are subject to risks and
uncertainties that could materially affect the Company including those risks
and uncertainties described in the documents Axonyx files from time to time
with the SEC, specifically Axonyx’s annual report on Form 10-K. Axonyx cannot
assure that the Phase IIB and/or the Phase III clinical trial, or others, if
any, with Phenserine will prove successful, that the safety and efficacy
profile of Phenserine exhibited in the previous small Phase II trial will
remain the same in the Phase IIB and Phase III clinical trials, or future
clinical trials, if any, that the preclinical results related to the regulation
of beta-APP will be substantiated by the Phenserine Phase IIB clinical trial
and that Phenserine will be able to slow the progression of Alzheimer’s
disease, that the Phase IIB clinical trial data will differentiate Phenserine
from the currently marketed drugs, that the efficacy results of the Phase III
trial will prove pivotal, that the efficacy data from the Phase IIB clinical
trial will be able to be used in the Phase III trial efficacy data, that Axonyx
will obtain the necessary financing to complete the Phase III Phenserine
trials, that the Company’s development work on Phenserine will support an NDA
filing, that the results of the Phase III trials will allow Phenserine to be
approved by the FDA, that the FDA will grant marketing approval for Phenserine,
that if Phenserine is approved by the FDA, it will prove competitive in the
market, and that Axonyx will obtain licensing or corporate partnership
agreements that will enable acceleration of the development of and optimize
marketing opportunities for, Phenserine, or that Axonyx will be able to advance
any other potential memory enhancing compound toward IND status. Axonyx
undertakes no obligation to publicly release the result of any revisions to
such forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
end of message, (c)DGAP 10.12.2003
——————————————————————————–
WKN: 928329; ISIN: US05461R1014; Index:
Listed: Freiverkehr in Frankfurt und Berlin-Bremen;
101859 Dez 03
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden